Want to see JP:6568 full AI Analyst Report?

KNC Laboratories Co.,Ltd. (6568) Price & Analysis

0 Followers

6568 Stock Chart & Stats

¥1124.00

¥0.00(0.00%)

At close: Jan 08 4:00 PM EST

¥1124.00

¥0.00(0.00%)

Day’s Range― - ―

52-Week Range¥1,060.00 - ¥1,418.00

Previous CloseN/A

Volume3.20K

Average Volume (3M)3.20K

Market Cap

¥9.50B

Enterprise Value¥11.01K

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)11.5

Beta0.48

Next Earnings

Nov 06, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield2.7%

Share Statistics

EPS (TTM)5.30

Shares Outstanding7,779,900

10 Day Avg. Volume3,050

30 Day Avg. Volume3,200

Financial Highlights & Ratios

PEG Ratio3.29

Price to Book (P/B)0.67

Price to Sales (P/S)1.04

P/FCF Ratio-26.14

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)208.6

Revenue Forecast (FY)¥12.00B

Bulls Say, Bears Say

Bulls Say

2026 Revenue ReboundThe return to double-digit revenue growth indicates renewed demand or improved commercial execution after the 2025 decline. Sustained top-line recovery could support operating scale, although future benefit depends on restoring margins.

Strong Balance SheetSteady equity growth and historically moderate leverage provide financial resilience and borrowing capacity. This capitalization can help the company fund operations and investment through weaker profit periods without excessive balance-sheet strain.

Improved Operating Cash FlowThe recovery in operating cash flow suggests that underlying cash generation improved despite recent earnings pressure. If maintained, stronger operating inflows could restore funding flexibility and help finance investment with less reliance on additional debt.

Bears Say

Material Profitability CompressionLower operating profit and net income indicate that the recent revenue rebound has not yet translated into comparable earnings power. Persistent pressure from pricing, product mix, or input costs could limit returns and weaken the durability of growth.

Two Years Of Negative Free Cash FlowRepeatedly negative free cash flow reduces flexibility for debt reduction, shareholder distributions, and self-funded expansion. Even with improved operating cash flow, continued investment needs or weak cash conversion could require external financing.

Recent Debt BuildAlthough leverage remains manageable, rising debt increases financial risk while margins and free cash flow are under pressure. If earnings recovery stalls, additional borrowing could constrain investment capacity and raise dependence on balance-sheet funding.

6568 FAQ

What was KNC Laboratories Co.,Ltd.’s price range in the past 12 months?

KNC Laboratories Co.,Ltd. lowest stock price was ¥1060.00 and its highest was ¥1418.00 in the past 12 months.

What is KNC Laboratories Co.,Ltd.’s market cap?

KNC Laboratories Co.,Ltd.’s market cap is ¥9.50B.

When is KNC Laboratories Co.,Ltd.’s upcoming earnings report date?

KNC Laboratories Co.,Ltd.’s upcoming earnings report date is Nov 06, 2026 which is in 43 days.

How were KNC Laboratories Co.,Ltd.’s earnings last quarter?

KNC Laboratories Co.,Ltd. released its earnings results on Aug 07, 2026. The company reported ¥5.3 earnings per share for the quarter.

Is KNC Laboratories Co.,Ltd. overvalued?

According to Wall Street analysts KNC Laboratories Co.,Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does KNC Laboratories Co.,Ltd. pay dividends?

KNC Laboratories Co.,Ltd. pays a Semiannually dividend of ¥16 which represents an annual dividend yield of 2.7%. See more information on KNC Laboratories Co.,Ltd. dividends here

What is KNC Laboratories Co.,Ltd.’s EPS estimate?

KNC Laboratories Co.,Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does KNC Laboratories Co.,Ltd. have?

KNC Laboratories Co.,Ltd. has 7,779,900 shares outstanding.

What happened to KNC Laboratories Co.,Ltd.’s price movement after its last earnings report?

KNC Laboratories Co.,Ltd. reported an EPS of ¥5.3 in its last earnings report. Following the earnings report the stock price went up 0.079%.

Which hedge fund is a major shareholder of KNC Laboratories Co.,Ltd.?

Currently, no hedge funds are holding shares in JP:6568

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

KNC Laboratories Co.,Ltd.

KNC Laboratories Co., Ltd. engages in research, development, and production solutions for organic chemicals. Its operations are carried out through the following business divisions: Functional Materials Business, Pharmaceutical Business, and Bio Business. The Functional Materials Business division provides display materials, chemicals for semiconductor manufacturing, carbon nanotube dispersions, etc. The Pharmaceutical Business division provides compounds for pharmaceutical research and development. The Bio Business Division provides auxiliary agents for antibody drug manufacturing. The company was founded on January 22, 1985 and is headquartered in Kobe, Japan.